Edition:
United Kingdom

People: PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

29.68USD
15 Feb 2019
Change (% chg)

$0.63 (+2.17%)
Prev Close
$29.05
Open
$29.20
Day's High
$29.73
Day's Low
$29.06
Volume
221,271
Avg. Vol
296,774
52-wk High
$52.95
52-wk Low
$22.81

Schmertzler, Michael 

Mr. Michael Schmertzler is Independent Chairman of the Board of PTC Therapeutics, Inc. From 2001 to 2015, Mr. Schmertzler served as a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P., a private equity fund, and the Chair of the investment committee of Credit Suisse First Boston Equity Partners, L.P. From 1997 to 2001, Mr. Schmertzler was Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking firm. Prior to 1997, Mr. Schmertzler held various management positions with Morgan Stanley and its affiliates, including President of Morgan Stanley Leveraged Capital Funds and head of Morgan Stanley's biotechnology pharmaceuticals group, and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb and Head of International Sales and Trading and Investment Banking at its successor, Lehman Brothers, both investment banking firms. Mr. Schmertzler is currently a director of Lehman Commercial Paper Incorporated, a liquidating post-bankruptcy subsidiary of Lehman Brothers Holdings, Incorporated. From 2008 to 2012, Mr. Schmertzler served as Chief Executive Officer and a director of Kolltan Pharmaceuticals, Inc., a Yale University biotechnology spin-out. Mr. Schmertzler previously served as a director of Cytokinetics, Inc., and Idenix Pharmaceuticals, Inc., both of which are public biopharmaceutical companies. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer at Yale University. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 66,577
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 175,600
Fiscal Year Total, USD 242,177

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Schmertzler

242,177

Stuart Peltz

2,172,680

Christine Utter

870,741

Marcio Souza

1,524,270

Neil Almstead

951,918

Mark Boulding

1,121,910
As Of  31 Dec 2017